Sangamo's Bankruptcy Leads to Astellas' Acquisition of ST-920 and Plans for Seraph Bio's Indirect Listing
Sangamo's Bankruptcy Filing and Big Pharma's Asset Sales
Sangamo Therapeutics (SGMO), a pioneer in Zinc Finger gene editing, has filed for voluntary Chapter 11 bankruptcy protection. Eli Lilly (LLY) and Astellas Pharma are key bidders in the sale of core assets. Lilly plans to acquire the capsid platform and the prion therapy ST-506 for $50 million, while Astellas has submitted a proposal to acquire the Fabry disease gene therapy isaralgagene sirveparvovec (ST-920) for up to $50 million. This deal suggests that while independent commercialization has failed, the platform's technological value is still highly recognized by global big pharma companies.
Seraph Bio's Indirect Listing and $230 Million Funding
Gene editing biotech Seraph Bio is planning an indirect listing on Nasdaq through a reverse merger with Boundless Bio (BOLD). Seraph has simultaneously secured $230 million in private placement funding led by RA Capital, providing funding for clinical trials. These funds will be used for clinical trials of SERP-01, a base editing pipeline for alpha-1 antitrypsin deficiency (AATD) acquired from YolTech in China. This clearly demonstrates the recent trend of overseas technology transfer, aiming to quickly establish high-quality Chinese technology assets in Western markets.
Sanofi's Cenrifki Approved in Europe, Faces Regulatory Hurdles in the US
Sanofi (SNY)'s multiple sclerosis treatment Cenrifki (active ingredient: tolebrutinib) has received final approval from the European Commission (EC), paving the way for its first commercial launch. Cenrifki, a BTK inhibitor that crosses the blood-brain barrier, has demonstrated efficacy in delaying disability progression in patients with relapsing-remitting secondary progressive multiple sclerosis (SPMS), making it the first approved treatment in Europe. However, the US FDA rejected the application earlier this year due to concerns about drug-induced liver injury, resulting in a stark contrast in the regulatory approaches of the two major regulatory bodies. Sanofi needs to strengthen monitoring in the European market and revise its US application.
Carsgen's Satri-cel Receives World's First CAR-T Approval in China for Solid Tumors
Carsgen Therapeutics has received regulatory approval in China for satri-cel, a CAR-T therapy targeting solid tumors, marking the world's first approval. Satri-cel is indicated for the treatment of gastric cancer patients expressing Claudin 18.2. It overcomes the limitations of existing cell therapies that have repeatedly failed in solid tumors due to the immunosuppressive tumor microenvironment, demonstrating its innovative potential in reaching commercialization. This is expected to reshape the competitive landscape of the Claudin 18.2 target market and further intensify competition in the global biopharmaceutical sector for solid tumor treatments.
The sale of Sangamo's core assets will drive a re-evaluation of the value of its patents and pipelines, providing a new benchmark for transaction valuations in the gene editing market. The $230 million in funding secured by Seraph Bio will be primarily used to accelerate global Phase 3 clinical trials for BEAM-302, a competing treatment in the alpha-1 antitrypsin deficiency (AATD) market, developed by Beam Therapeutics (BEAM). Furthermore, Carsgen's world's first approval of satri-cel, a CAR-T therapy for solid tumors, by the NMPA is a significant achievement, demonstrating the commercial potential of the Claudin 18.2 target market in the global gastric cancer market, estimated at approximately $15 billion. Sanofi's European approval of Cenrifki and the FDA's rejection in the US are expected to lead to adjustments in market share acquisition speed in the approximately $30 billion multiple sclerosis market due to regulatory uncertainty. These individual events confirm that selective deal structures and regulatory risk management capabilities in the gene and cell therapy fields are key variables in determining investment returns in the bio sector.
Source: BioPharma Dive (rss)